Instagram Live Today: Ozempic/Wegovy/Mounjaro/Zepbound updates!

Two years ago, I interviewed Dr. Karl Nadolsky and Dr. Fatima Cody Stanford to discuss Ozempic and Wegovy. That interview caused me to take a close look at the literature on these and other GLP-1 drugs—and I was simply blown away.

Since then, I’ve been routinely amazed by the medical literature, and I’ve covered important developments here in Inside Medicine. Indeed GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are revolutionizing medicine in many different and exciting ways, from diabetes, to heart disease, liver disease, kidney disease…and, of course, obesity in general.

I’m so excited to have the chance to speak to the very two experts who tuned me into these incredible medications in the first place, and get some key updates.

📢 Join me for an exclusive Instagram Live to explore the latest findings and their cultural impact. We’ll be live TODAY Monday, December 2, at 2 PM ET.

To watch live, follow @medpage on IG to tune in: https://www.instagram.com/medpage/

Please add your questions in the Comments section below

Also, for those who have not upgraded already, today is the last day of the Thanksgiving Weekend Holiday Sale. So, if you have a question for Dr. Nadolsky, Dr. Stanford, or me, and you haven’t already joined the brilliant group of Premium subscribers, now’s the time to upgrade and join the conversation!

See you soon! —Jeremy